TCTMD

First-line Ablation Reduces AF Progression, Boosts Quality of Life

CHICAGO, IL—In a population of patients with paroxysmal atrial fibrillation (AF) deemed to be at low risk of progression, first-line cryoballoon ablation reduced the likelihood of developing ...
Seeking Alpha

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

TUKYSA, trastuzumab, and pertuzumab reduced the risk of disease progression or death by 36% compared to trastuzumab and pertuzumab alone in Phase 3 HER2CLIMB-05 study The combination demonstrated a ...
Seeking Alpha

Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 ...

– With Two Positive Phase 3 Trials, Trodelvy Has Potential as the First and Only ADC to be a Backbone Standard of Care for All First-Line Metastatic TNBC Patients Regardless of PD-L1 Status – ...
EurekAlert!

Adding tucatinib to first-line maintenance therapy delayed disease progression in HER2-positive metastatic breast cancer in HER2CLIMB-05 trial

SAN ANTONIO – Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic ...
MedPage Today

Less Than Half of Patients with Recurrent or Metastatic Cervical Cancer Receive Second-Line Therapy Following Disease Progressions

Cervical cancer is largely preventable but remains an important cause of cancer mortality in the United States. Less than half of women who complete first-line therapy for r/mCC receive second-line ...
ascopubs.org

Survival outcomes in patients (pts) with Child-Pugh class B (CP-B) liver function at progression after first-line atezolizumab-bevacizumab (Atezo-Bev) for unresectable ...

Clinical determinants of survival and a predictive immune biomarker for immunotherapy in fibrolamellar carcinoma: A comprehensive institutional analysis. This is an ASCO Meeting Abstract from the 2026 ...